Abel E L
NIDA Res Monogr. 1985;59:20-35.
Prenatal exposure to cannabinoids does not produce gross malformations in humans and only does so with any consistency in mice following exposure to relatively high doses and following the intraperitoneal route of administration. Resorption rates are reliably increased in mice but not rats following in utero cannabinoid exposure. There is also a reliable decrease in maternal food and water consumption and weight gain during pregnancy associated with maternal cannabinoid administration. This effect may account for many of the effects associated with prenatal exposure to cannabinoids, e.g., increased resorption rate. Prenatal exposure to cannabinoids produces a reliable decrease in birth weight in animals, but this is the only postnatal effect on offspring that has been reliably documented. Studies examining long-term postnatal effects are generally inconsistent. This inconsistency may be due to methodological flaws in experimental design, such as absence of controls for drug-related undernutrition and residual effects of maternal cannabinoid exposure during postnatal nursing. When such controls have been implemented, postnatal effects of prenatal cannabinoid exposure have not been reliably observed.
产前接触大麻素不会导致人类出现严重畸形,只有在小鼠接触相对高剂量且通过腹腔注射途径给药时,才会较为一致地出现这种情况。子宫内接触大麻素后,小鼠的吸收率确实会增加,但大鼠不会。孕期母体给予大麻素还会导致母体食物和水的摄入量以及体重增加出现可靠的下降。这种影响可能解释了许多与产前接触大麻素相关的效应,例如吸收率增加。产前接触大麻素会使动物出生体重可靠地降低,但这是唯一有可靠记录的对后代的产后影响。研究产后长期影响的结果通常并不一致。这种不一致可能是由于实验设计中的方法学缺陷,例如缺乏对与药物相关的营养不良以及产后护理期间母体大麻素接触的残留影响的控制。当实施这些控制措施后,并未可靠地观察到产前大麻素接触的产后影响。